Covid-19: Critical Lessons for the Survival of Mankind from the Present and Future Pneumonic Viral Infections

K. K. Sharma

One who wins without problems, it is just “VICTORY,” but,

One who wins with lot of troubles, it is “HISTORY”.

Covid-19, the short for Coronavirus Disease (occurring in) 2019, hit the world with a bang, beginning from Wuhan, the capital of Hubei province in China. Tracing the history, the first case (P-zero) was detected on December 8, 2019 (now recognized to be a woman of 57 years, who sold shrimps in the Huanan market admitted in the Wuhan Union Hospital on December 10 and diagnosed on December 31 with Covid-19) before several workers from the Huanan seafood market started to fall sick with fever and respiratory symptoms of shortness of breath, sneezing and cough, and some with dyspnea and signs of pneumonitis.[1] [2] Three weeks later on December 31, Wuhan Health Authorities announced a series of 21 cases of suspected pneumonia of unknown origin, all linked to seafood market, and notified to the World Health Organization (WHO) country office in China.[2] [3] The disease appeared to be highly infectious, causing considerable anxiety among physicians. Within a month, 41 patients were getting treatment for this unique infection in the Wuhan Union Hospital, where one of them died in the meantime (but the P-zero is still surviving). Due to fast-spreading transmission events, Covid-19 cases were widespread not only across mainland China but also beyond Chinese borders by January 21, 2020, as a result of symptomatic/asymptomatic international or national travelers returning to their native countries or other states of China, respectively. On January 30, 2020, the International Health Regulations Emergency Committee (IHREC) of WHO declared the disease epidemic as Public Health Emergency of International Concern (PHEIC), because as of January 27, more than 2000 cases had been diagnosed in several other countries, besides China and Hongkong: Thailand, Japan, South Korea, Singapore, Vietnam, Taiwan, Nepal, Macao, Australia, France, Canada, and US. Most of these patients were living in, visited Wuhan, or were their contacts.[1] [2] [3] Human-to-human transmission was confirmed.[4]

Publikationsverlauf

Artikel online veröffentlicht:
18. Mai 2020

• References

• 1 Zhou P, Yang XL, Wang XG. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020;
• 2 Zhu N, Zhang D, Wang W. et al. China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020; 382 (08) 727-733
• 3 World Health Organization. Novel coronavirus – China Disease Outbreak news: update 12 January (cited 2020 Feb 12). Available at: https://www.who.int/CSR/don/12-Jan-2020-novelcoronavirus-China/en. Accessed March 16, 2020
• 4 Li Q, Guan X, Wu P. et al. Early transmission dynamics in Wuhan, China of novel coronavirus-infected pneumonia. N Engl J Med 2020; 382 (13) 1199-1207
• 5 Corman VM, Landt O, Kaiser M. et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill 2020; 25 (03) 2000045
• 6 Lu R, Zhao X, Li J. et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020; 395 (10224) 565-574
• 7 Chan JFW, Yuan S, Kok KH. A familial cluster of pneumonia associated with 2019 novel coronavirus indicating person-to-person transmission. Lancet 2020; 395 (10223) 514-523
• 8 Huang C, Wang Y, Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395 (10223) 497-506
• 9 World Health Organization. Global Surveillance for Human Infection with Coronavirus Disease (COVID-19). Available at: https://www.who.int/publications-detail/global-surveillance-for-human-infection-with-novel-coronavirus-(2019-ncov). Accessed April 18, 2020
• 10 World Health Organization. Middle East Respiratory Syndrome Coronavirus (MERS-CoV). Available at: https://www.who.int/emergencies/mers-cov/en/. Accessed March 16, 2020
• 11 Xu Z, Shi L, Wang Y. et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020; 8 (04) 420-422
• 12 Chinese Centre for Disease Control and Prevention. The epidemiological characteristics of an outbreak of 2019 novel coronavirus disease (COVID-19)-China. Available at: https://weeklychmacdc.cn/en/article/id/e53946e2c6e4–4-e9–9a9b-fea8db1a8f51. Accessed March 16, 2020
• 13 Walker PGT, Whittaker C, Watson O. et al. The Global Impact of COVID-19 and Strategies for Mitigation and Suppression. London: Imperial College; 2020: 1-19
• 14 Cascella M, Rajnik M, Cuomo A. et al. Features evaluation and treatment of coronavirus (COVID-19). In: SatPearls [Internet]. Treasure Island (FL): Sat Pearls Publishing; 2020
• 15 Wang M, Cao R, Zhang L. et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 30 (03) 269-271
• 16 Anonymous. Revised Guideline on Clinical Management of COVID-19. New Delhi: Directorate General of Health Services (EMR Division), Ministry of Health & Family Welfare, Govt. of India, p. 1–18. Available at: https://www.mohfw.gov.in/pdf/RevisedNationalClinicalManagementGuidelineforCOVID1931032020.pdf. Accessed April 18, 2020